Suppr超能文献

头孢洛扎与他唑巴坦联用对中性粒细胞减少小鼠大腿模型中肠杆菌科细菌的药效学研究

Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

作者信息

Melchers M J, Mavridou E, van Mil A C, Lagarde C, Mouton J W

机构信息

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.

出版信息

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7272-7279. doi: 10.1128/AAC.01580-16. Print 2016 Dec.

Abstract

Ceftolozane is a new broad-spectrum cephalosporin and is combined with tazobactam to broaden the activity of ceftolozane against strains producing extended-spectrum beta-lactamases (ESBLs). We determined the pharmacodynamics (PD) of the combination in the neutropenic mouse thigh model to determine the optimal exposure of tazobactam. Treatment of CD-1 neutropenic mice was started 2 h after infection with ceftolozane every 2 h (q2h) alone or in combination with tazobactam at different dosing frequencies for 24 h, and the number of CFU in the thighs was determined before and after treatment. The maximum effect model was fit to the dose-response and the pharmacokinetic/PD index (PDI)-response to determine the PDI values for ceftolozane alone and ceftolozane in combination with tazobactam resulting in a static effect and a 1-log kill. The effect of tazobactam was dependent on the percentage of time that the free drug concentration remained above the concentration threshold (percent [Formula: see text]), whereby dosing q2h was more efficacious than dosing every 8 h (q8h), reducing the tazobactam daily dose by a factor 6.9 to 59.0 (n = 3 strains) to obtain a static effect. Using R as an indicator of the best fit of the percent [Formula: see text]-response relationships, the concentration threshold best correlating with the response varied from 0.5 to 2 mg/liter, depending on the strain. A similar result was obtained when the q2h and q8h regimens were analyzed. For all isolates tested, the mean [Formula: see text] for 0.5 mg/liter tazobactam was 28.2% (range, 17.5 to 45.8%) and 44.4% (range, 26.6 to 54.7%) for a static effect and a 1-log kill, respectively, at ceftolozane exposures that produced a ceftolozane concentration of 4 mg/liter (a concentration greater than the MIC) for 33.9 to 63.3% of a 24-h period under steady-state pharmacokinetic conditions. The main PDI that correlated with the effect of tazobactam was the [Formula: see text] achieved with a C of 0.5 mg/liter tazobactam.

摘要

头孢洛扎是一种新型广谱头孢菌素,与他唑巴坦联合使用可扩大头孢洛扎对产超广谱β-内酰胺酶(ESBLs)菌株的活性。我们在中性粒细胞减少小鼠大腿模型中确定了该联合用药的药效学(PD),以确定他唑巴坦的最佳暴露量。CD-1中性粒细胞减少小鼠在感染后2小时开始治疗,每2小时(q2h)单独给予头孢洛扎或与他唑巴坦以不同给药频率联合给药24小时,并在治疗前后测定大腿中的菌落形成单位(CFU)数量。将最大效应模型拟合到剂量反应和药代动力学/药效学指数(PDI)反应,以确定单独使用头孢洛扎以及头孢洛扎与他唑巴坦联合使用导致静态效应和1个对数杀灭的PDI值。他唑巴坦的效果取决于游离药物浓度保持高于浓度阈值的时间百分比(百分比[公式:见正文]),因此q2h给药比每8小时(q8h)给药更有效,将他唑巴坦的每日剂量降低了6.9至59.0倍(n = 3株)以获得静态效应。使用R作为百分比[公式:见正文]-反应关系最佳拟合的指标,与反应最相关的浓度阈值在0.5至2 mg/升之间变化,具体取决于菌株。分析q2h和q8h给药方案时也得到了类似结果。对于所有测试的分离株,在稳态药代动力学条件下,在24小时期间的33.9%至63.3%时间内产生4 mg/升头孢洛扎浓度(高于最低抑菌浓度的浓度)的头孢洛扎暴露量下,0.5 mg/升他唑巴坦的平均[公式:见正文]对于静态效应分别为28.2%(范围为17.5%至45.8%),对于1个对数杀灭为44.4%(范围为26.6%至54.7%)。与他唑巴坦效果相关的主要PDI是0.5 mg/升他唑巴坦的C值所实现的[公式:见正文]。

相似文献

1
Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7272-7279. doi: 10.1128/AAC.01580-16. Print 2016 Dec.
2
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.
3
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an Infection Model.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01052-17. Print 2017 Dec.
4
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.
6
7
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Antimicrob Agents Chemother. 2015 Aug;59(8):4521-5. doi: 10.1128/AAC.04498-14. Epub 2015 May 18.
9
Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Antimicrob Agents Chemother. 2015;59(6):3373-6. doi: 10.1128/AAC.04402-14. Epub 2015 Mar 30.

引用本文的文献

2
What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.
J Antimicrob Chemother. 2024 May 2;79(5):946-958. doi: 10.1093/jac/dkae058.
3
Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.
Antibiotics (Basel). 2024 Jan 11;13(1):72. doi: 10.3390/antibiotics13010072.
4
In vitro and in vivo evaluation of two combined β-lactamase inhibitors against carbapenem-resistant Acinetobacter baumannii.
Eur J Clin Microbiol Infect Dis. 2023 Nov;42(11):1317-1325. doi: 10.1007/s10096-023-04664-z. Epub 2023 Sep 15.
5
Individualized antibiotic dosage regimens for patients with augmented renal clearance.
Front Pharmacol. 2023 Jul 26;14:1137975. doi: 10.3389/fphar.2023.1137975. eCollection 2023.
10
Sigmoid Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0092621. doi: 10.1128/AAC.00926-21.

本文引用的文献

1
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):368-75. doi: 10.1128/AAC.01269-15. Print 2016 Jan.
2
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Antimicrob Agents Chemother. 2015 Aug;59(8):4521-5. doi: 10.1128/AAC.04498-14. Epub 2015 May 18.
3
Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Antimicrob Agents Chemother. 2015;59(6):3373-6. doi: 10.1128/AAC.04402-14. Epub 2015 Mar 30.
4
Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.
Clin Infect Dis. 2015 May 1;60(9):1389-97. doi: 10.1093/cid/civ020. Epub 2015 Jan 16.
5
Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.
Antimicrob Agents Chemother. 2015 Feb;59(2):790-5. doi: 10.1128/AAC.03706-14. Epub 2014 Nov 17.
7
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.
8
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.
9
Proliferation and significance of clinically relevant β-lactamases.
Ann N Y Acad Sci. 2013 Jan;1277:84-90. doi: 10.1111/nyas.12023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验